Ketamine-enhanced Prolonged Exposure Therapy in PTSD

• Status: Recruiting
• Trial end date: 2024-09-17
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Ketamine; Midazolam

Criteria

Inclusion Criteria:

• male or female Veterans between the ages of 18 and 75 years

• diagnosis of PTSD

• ability to provide written informed consent

Exclusion Criteria:

• females who are currently pregnant or breastfeeding

• current high risk for suicide

• history of moderate/severe head injury

• history of psychosis

• current episode of mania/hypomania

• severe substance and/or alcohol use disorder in the last 6 months